| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_466531f15ea1dcf47d690d28d7564968 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2310-32
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2310-351
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/Y10S514-894
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2310-113
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2310-11
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2310-31 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K48-0075
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K48-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-713
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-20
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-107
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-127
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-5161
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-51
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-1131 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K48-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-51
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-107
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-127 |
| filingDate |
2017-12-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e95211e60e92643f2ef883b67350c434
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d7cece17374e62d895985e6a09c4400f
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_bd78d194075c1e9a6ba143cb6a196e34 |
| publicationDate |
2018-06-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
KR-20180068320-A |
| titleOfInvention |
Pharmaceutical composition for preventing or treating hepatitis b |
| abstract |
The present invention provides oligonucleotides represented by the nucleic acid sequences of SEQ ID NO: 1, 2 or 6 or their complementary nucleic acid sequences; And oligonucleotides having at least one chemical modification on the oligonucleotide; and a pharmaceutical composition for treating or preventing hepatitis B comprising one or more oligonucleotides selected from the group consisting of HBV and a candidate The present invention relates to a screening method of a hepatitis B therapeutic agent depending on whether a substance forms a G-quadruplex. The medicinal composition can be used for the treatment or prevention of hepatitis B by forming HBV and guanine-4 polymer and reducing covalently closed circular DNA of HBV. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2019240504-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2019240503-A1 |
| priorityDate |
2016-12-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |